최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.28 no.6 = no.218, 2018년, pp.753 - 763
Cysteine cathepsins are lysosomal enzymes that belong to the papain family and can induce the degradation of damaged proteins through the endo-lysosomal pathway. It is highly upregulated in many cancers by regulating gene amplification and transcriptional, translational, and post-transcriptional mod...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
리소좀은 무엇인가? | 리소좀(Lysosome)은 최적 pH가 산성인 세포 내 소기관으로 protease, glycosidase, lipase, nuclease와 같은 50개가 넘는 가수분해효소를 가지고 있다. 따라서 endocytosis이나 식균작용(phagocytosis)에 의해 유입된 모든 유형의 거대분자를 분해하고 재사용 여부를 결정하기 때문에, 리소좀은 세포의 항상성 조절에 있어 매우 중요하다[2, 70]. | |
Protease가 단백질을 분해하는 방법은? | Protease는 공유결합으로 연결된 아미노산의 펩티드 결합을 가수분해시킴으로써 단백질을 분해하는 기능을 가진 효소이다[72]. 이러한 protease는 단순히 단백질의 분해와 합성을 조절할 뿐만 아니라 뼈를 재구성하거나 항원 제시 및 여러가지 질병과 같은 다양한 범위의 생리학적 과정에 영향을 미친다[29, 99, 102]. | |
Protease는 인체 내에서 어떤 영향을 미치는가? | Protease는 공유결합으로 연결된 아미노산의 펩티드 결합을 가수분해시킴으로써 단백질을 분해하는 기능을 가진 효소이다[72]. 이러한 protease는 단순히 단백질의 분해와 합성을 조절할 뿐만 아니라 뼈를 재구성하거나 항원 제시 및 여러가지 질병과 같은 다양한 범위의 생리학적 과정에 영향을 미친다[29, 99, 102]. 현재 많은 protease가 암이나 자가면역, 심혈관계 질환 및 신경 퇴행성질환을 치료하는 타겟으로 여겨지고 있다[59, 94, 96]. |
Alatrash, G., Garber, H. R., Zhang, M., Sukhumalchandra, P., Qiu, Y., Jakher, H., Perakis, A. A., Becker, L., Yoo, S. Y., Dwyer, K. C., Coombes, K., Talukder, A. H., John, L. S. S., Senyukov, V., Lee, D. A., Sergeeva, A., He, H., Ma, Q., Armistead, P. M., Roszik, J., Mittendorf, E. A., Molldrem, J. J., Hawke, D., Lizee, G. and Kornblau, S. M. 2017. Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target. Leukemia 31, 234-237.
Appelqvist, H., Waster, P., Kagedal, K. and Ollinger, K. 2013. The lysosome: from waste bag to potential therapeutic target. J. Mol. Cell. Biol. 5, 214-226.
Azuma, T., Yamada, M., Murakita, H., Nishikawa, Y., Kohli, Y., Yamamoto, K. and Hori, H. 1995. Cathepsin E expressed in pancreatic cancer. Adv. Exp. Med. Biol. 362, 363-366.
Barrett, A. J., Kembhavi, A. A., Brown, M. A., Kirschke, H., Knight, C. G., Tamai, M. and Hanada, K. 1982. L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L. Biochem. J. 201, 189-198.
Baugh, M., Black, D., Westwood, P., Kinghorn, E., McGregor, K., Bruin, J., Hamilton, W., Dempster, M., Claxton, C., Cai, J., Bennett, J., Long, C., McKinnon, H., Vink, P., den Hoed, L., Gorecka, M., Vora, K., Grant, E., Percival, M. D., Boots, A. M. and van Lierop, M. J. 2011. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J. Autoimmun. 36, 201-209.
Bell-McGuinn, K. M., Garfall, A. L., Bogyo, M., Hanahan, D. and Joyce, J. A. 2007. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 67, 7378-7385.
Berger, A. B., Vitorino, P. M. and Bogyo, M. 2004. Activitybased protein profiling: applications to biomarker discovery, in vivo imaging and drug discovery. Am. J. Pharmacogenomics 4, 371-381.
Burden, R. E., Gormley, J. A., Jaquin, T. J., Small, D. M., Quinn, D. J., Hegarty, S. M., Ward, C., Walker, B., Johnston, J. A., Olwill, S. A. and Scott, C. J. 2009. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis. Clin. Cancer Res. 15, 6042-6051.
Burden, R. E., Gormley, J. A., Kuehn, D., Ward, C., Kwok, H. F., Gazdoiu, M., McClurg, A., Jaquin, T. J., Johnston, J. A., Scott, C. J. and Olwill, S. A. 2012. Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie 94, 487-493.
Chai, Y., Wu, W., Zhou, C. and Zhou, J. 2012. The potential prognostic value of cathepsin D protein in serous ovarian cancer. Arch. Gynecol. Obstet. 286, 465-471.
Chauhan, S. S., Goldstein, L. J. and Gottesman, M. M. 1991. Expression of cathepsin L in human tumors. Cancer Res. 51, 1478-1481.
Chen, J. C., Uang, B. J., Lyu, P. C., Chang, J. Y., Liu, K. J., Kuo, C. C., Hsieh, H. P., Wang, H. C., Cheng, C. S., Chang, Y. H., Chang, M. D., Chang, W. S. and Lin, C. C. 2010. Design and synthesis of alpha-ketoamides as cathepsin S inhibitors with potential applications against tumor invasion and angiogenesis. J. Med. Chem. 53, 4545-4549.
Chen, K. L., Chang, W. S., Cheung, C. H., Lin, C. C., Huang, C. C., Yang, Y. N., Kuo, C. P., Kuo, C. C., Chang, Y. H., Liu, K. J., Wu, C. M. and Chang, J. Y. 2012. Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Lett. 317, 89-98.
Codogno, P. and Meijer, A. J. 2005. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12 Suppl 2, 1509-1518.
Conus, S. and Simon, H. U. 2010. Cathepsins and their involvement in immune responses. Swiss Med. Wkly. 140, w13042.
Costantino, C. M., Ploegh, H. L. and Hafler, D. A. 2009. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells. J. Immunol. 183, 945-952.
Decock, J., Obermajer, N., Vozelj, S., Hendrickx, W., Paridaens, R. and Kos, J. 2008. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer. Int. J. Biol. Markers 23, 161-168.
Dian, D., Vrekoussis, T., Shabani, N., Mylonas, I., Kuhn, C., Schindlbeck, C., Navrozoglou, I., Friese, K., Makrigiannakis, A. and Jeschke, U. 2012. Expression of cathepsin-D in primary breast cancer and corresponding local recurrence or metastasis: an immunohistochemical study. Anticancer Res. 32, 901-905.
Drenth, J., Jansonius, J. N., Koekoek, R., Swen, H. M. and Wolthers, B. G. 1968. Structure of papain. Nature 218, 929-932.
Drevs, J., Muller-Driver, R., Wittig, C., Fuxius, S., Esser, N., Hugenschmidt, H., Konerding, M. A., Allegrini, P. R., Wood, J., Hennig, J., Unger, C. and Marme, D. 2002. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res. 62, 4015-4022.
Driessen, C., Bryant, R. A., Lennon-Dumenil, A. M., Villadangos, J. A., Bryant, P. W., Shi, G. P., Chapman, H. A. and Ploegh, H. L. 1999. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J. Cell Biol. 147, 775-790.
Ebert, M. P., Kruger, S., Fogeron, M. L., Lamer, S., Chen, J., Pross, M., Schulz, H. U., Lage, H., Heim, S., Roessner, A., Malfertheiner, P. and Rocken, C. 2005. Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5, 1693-1704.
Fan, Q., Wang, X., Zhang, H., Li, C., Fan, J. and Xu, J. 2012. Silencing cathepsin S gene expression inhibits growth, invasion and angiogenesis of human hepatocellular carcinoma in vitro. Biochem. Biophys. Res. Commun. 425, 703-710.
Fan, X., Wang, C., Song, X., Liu, H., Li, X. and Zhang, Y. 2018. Elevated Cathepsin K potentiates metastasis of epithelial ovarian cancer. Histol. Histopathol. 11960.
Fernandez, P. L., Farre, X., Nadal, A., Fernandez, E., Peiro, N., Sloane, B. F., Shi, G. P., Chapman, H. A., Campo, E. and Cardesa, A. 2001. Expression of cathepsins B and S in the progression of prostate carcinoma. Int. J. Cancer 95, 51-55.
Firestein, G. S. 2005. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J. Clin. Rheumatol. 11, S39-44.
Flannery, T., Gibson, D., Mirakhur, M., McQuaid, S., Greenan, C., Trimble, A., Walker, B., McCormick, D. and Johnston, P. G. 2003. The clinical significance of cathepsin S expression in human astrocytomas. Am. J. Pathol. 163, 175-182.
Flannery, T., McQuaid, S., McGoohan, C., McConnell, R. S., McGregor, G., Mirakhur, M., Hamilton, P., Diamond, J., Cran, G., Walker, B., Scott, C., Martin, L., Ellison, D., Patel, C., Nicholson, C., Mendelow, D., McCormick, D. and Johnston, P. G. 2006. Cathepsin S expression: An independent prognostic factor in glioblastoma tumours--A pilot study. Int. J. Cancer 119, 854-860.
Georges, S., Ruiz Velasco, C., Trichet, V., Fortun, Y., Heymann, D. and Padrines, M. 2009. Proteases and bone remodelling. Cytokine Growth Factor Rev. 20, 29-41.
Gocheva, V. and Joyce, J. A. 2007. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 6, 60-64.
Gocheva, V., Zeng, W., Ke, D., Klimstra, D., Reinheckel, T., Peters, C., Hanahan, D. and Joyce, J. A. 2006. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 20, 543-556.
Gong, F., Peng, X., Luo, C., Shen, G., Zhao, C., Zou, L., Li, L., Sang, Y., Zhao, Y. and Zhao, X. 2013. Cathepsin B as a potential prognostic and therapeutic marker for human lung squamous cell carcinoma. Mol. Cancer 12, 125.
Gormley, J. A., Hegarty, S. M., O'Grady, A., Stevenson, M. R., Burden, R. E., Barrett, H. L., Scott, C. J., Johnston, J. A., Wilson, R. H., Kay, E. W., Johnston, P. G. and Olwill, S. A. 2011. The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study. Br. J. Cancer 105, 1487-1494.
Huang, C. C., Chen, K. L., Cheung, C. H. and Chang, J. Y. 2013. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic. Biol. Med. 65, 1473-1486.
Ishida, M., Kojima, F. and Okabe, H. 2013. Cathepsin K expression in basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 27, e128-130.
Jechorek, D., Votapek, J., Meyer, F., Kandulski, A., Roessner, A. and Franke, S. 2014. Characterization of cathepsin X in colorectal cancer development and progression. Pathol. Res. Pract. 210, 822-829.
Jedinak, A. and Maliar, T. 2005. Inhibitors of proteases as anticancer drugs. Neoplasma 52, 185-192.
Johansson, A. C., Appelqvist, H., Nilsson, C., Kagedal, K., Roberg, K. and Ollinger, K. 2010. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis 15, 527-540.
Joyce, J. A., Baruch, A., Chehade, K., Meyer-Morse, N., Giraudo, E., Tsai, F. Y., Greenbaum, D. C., Hager, J. H., Bogyo, M. and Hanahan, D. 2004. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443-453.
Joyce, J. A. and Hanahan, D. 2004. Multiple roles for cysteine cathepsins in cancer. Cell Cycle 3, 1516-1619.
Kawakubo, T., Yasukochi, A., Toyama, T., Takahashi, S., Okamoto, K., Tsukuba, T., Nakamura, S., Ozaki, Y., Nishigaki, K., Yamashita, H. and Yamamoto, K. 2014. Repression of cathepsin E expression increases the risk of mammary carcinogenesis and links to poor prognosis in breast cancer. Carcinogenesis 35, 714-726.
Kirschke, H., Wiederanders, B., Bromme, D. and Rinne, A. 1989. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. J. 264, 467-473.
Kondo, Y., Kanzawa, T., Sawaya, R. and Kondo, S. 2005. The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5, 726-734.
Konduri, S., Lakka, S. S., Tasiou, A., Yanamandra, N., Gondi, C. S., Dinh, D. H., Olivero, W. C., Gujrati, M. and Rao, J. S. 2001. Elevated levels of cathepsin B in human glioblastoma cell lines. Int. J. Oncol. 19, 519-524.
Konno-Shimizu, M., Yamamichi, N., Inada, K., Kageyama- Yahara, N., Shiogama, K., Takahashi, Y., Asada-Hirayama, I., Yamamichi-Nishina, M., Nakayama, C., Ono, S., Kodashima, S., Fujishiro, M., Tsutsumi, Y., Ichinose, M. and Koike, K. 2013. Cathepsin E is a marker of gastric differentiation and signet-ring cell carcinoma of stomach: a novel suggestion on gastric tumorigenesis. PLoS One 8, e56766.
Kos, J., Sekirnik, A., Kopitar, G., Cimerman, N., Kayser, K., Stremmer, A., Fiehn, W. and Werle, B. 2001. Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis. Br. J. Cancer 85, 1193-1200.
Kozlowski, L., Wojtukiewicz, M. Z. and Ostrowska, H. 2000. Cathepsin A activity in primary and metastatic human melanocytic tumors. Arch. Dermatol. Res. 292, 68-71.
Kroemer, G. and Jaattela, M. 2005. Lysosomes and autophagy in cell death control. Nat. Rev. Cancer 5, 886-897.
Krueger, S., Kalinski, T., Hundertmark, T., Wex, T., Kuster, D., Peitz, U., Ebert, M., Nagler, D. K., Kellner, U., Malfertheiner, P., Naumann, M., Rocken, C. and Roessner, A. 2005. Up-regulation of cathepsin X in Helicobacter pylori gastritis and gastric cancer. J. Pathol. 207, 32-42.
Kruszewski, W. J., Rzepko, R., Wojtacki, J., Skokowski, J., Kopacz, A., Jaskiewicz, K. and Drucis, K. 2004. Overexpression of cathepsin B correlates with angiogenesis in colon adenocarcinoma. Neoplasma 51, 38-43.
Lecaille, F., Kaleta, J. and Bromme, D. 2002. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 102, 4459-4488.
Lee-Dutra, A., Wiener, D. K. and Sun, S. 2011. Cathepsin S inhibitors: 2004-2010. Expert Opin. Ther. Pat. 21, 311-337.
Leto, G., Incorvaia, L., Flandina, C., Ancona, C., Fulfaro, F., Crescimanno, M., Sepporta, M. V. and Badalamenti, G. 2016. Clinical impact of cystatin C/cathepsin L and follistatin/activin A systems in breast cancer progression: A preliminary report. Cancer Invest. 34, 415-423.
Leusink, F. K., Koudounarakis, E., Frank, M. H., Koole, R., van Diest, P. J. and Willems, S. M. 2018. Cathepsin K associates with lymph node metastasis and poor prognosis in oral squamous cell carcinoma. BMC Cancer 18, 385.
Levicar, N., Strojnik, T., Kos, J., Dewey, R. A., Pilkington, G. J. and Lah, T. T. 2002. Lysosomal enzymes, cathepsins in brain tumour invasion. J. Neurooncol. 58, 21-32.
Libby, P., Ridker, P. M. and Maseri, A. 2002. Inflammation and atherosclerosis. Circulation 105, 1135-1143.
Littlewood-Evans, A. J., Bilbe, G., Bowler, W. B., Farley, D., Wlodarski, B., Kokubo, T., Inaoka, T., Sloane, J., Evans, D. B. and Gallagher, J. A. 1997. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 57, 5386-5390.
Lohoefer, F., Reeps, C., Lipp, C., Rudelius, M., Zimmermann, A., Ockert, S., Eckstein, H. H. and Pelisek, J. 2012. Histopathological analysis of cellular localization of cathepsins in abdominal aortic aneurysm wall. Int. J. Exp. Pathol. 93, 252-258.
Lopez-Otin, C. and Bond, J. S. 2008. Proteases: multifunctional enzymes in life and disease. J. Biol. Chem. 283, 30433-30437.
MacIntyre, A. C. and Cutler, D. J. 1988. The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug Dispos. 9, 513-526.
Metaye, T., Kraimps, J. L., Goujon, J. M., Fernandez, B., Quellard, N., Ingrand, P., Barbier, J. and Begon, F. 1997. Expression, localization, and thyrotropin regulation of cathepsin D in human thyroid tissues. J. Clin. Endocrinol. Metab. 82, 3383-3388.
Nagler, D. K., Kruger, S., Kellner, A., Ziomek, E., Menard, R., Buhtz, P., Krams, M., Roessner, A. and Kellner, U. 2004. Up-regulation of cathepsin X in prostate cancer and prostatic intraepithelial neoplasia. Prostate 60, 109-119.
Nguyen, D. X. and Massague, J. 2007. Genetic determinants of cancer metastasis. Nat Rev. Genet 8, 341-352.
Nishikawa, H., Ozaki, Y., Nakanishi, T., Blomgren, K., Tada, T., Arakawa, A. and Suzumori, K. 2004. The role of cathepsin B and cystatin C in the mechanisms of invasion by ovarian cancer. Gynecol. Oncol. 92, 881-886.
Okudela, K., Mitsui, H., Woo, T., Arai, H., Suzuki, T., Matsumura, M., Kojima, Y., Umeda, S., Tateishi, Y., Masuda, M. and Ohashi, K. 2016. Alterations in cathepsin L expression in lung cancers. Pathol. Int. 66, 386-392.
Pandya, N. M., Dhalla, N. S. and Santani, D. D. 2006. Angiogenesis--a new target for future therapy. Vascul. Pharmacol. 44, 265-274.
Papetti, M. and Herman, I. M. 2002. Mechanisms of normal and tumor-derived angiogenesis. Am. J. Physiol. Cell Physiol. 282, C947-970.
Payne, C. D., Deeg, M. A., Chan, M., Tan, L. H., LaBell, E. S., Shen, T. and DeBrota, D. J. 2014. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Br. J. Clin. Pharmacol. 78, 1334-1342.
Petricevic, S. J., Pavlovic, A., Capkun, V., Becic, K. and Durdov, M. G. 2017. Cathepsin K expression in melanoma is associated with metastases. Histol. Histopathol. 32, 711-716.
Piao, S. and Amaravadi, R. K. 2016. Targeting the lysosome in cancer. Ann. N. Y. Acad. Sci. 1371, 45-54.
Pozgan, U., Caglic, D., Rozman, B., Nagase, H., Turk, V. and Turk, B. 2010. Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol. Chem. 391, 571-579.
Puente, X. S., Sanchez, L. M., Gutierrez-Fernandez, A., Velasco, G. and Lopez-Otin, C. 2005. A genomic view of the complexity of mammalian proteolytic systems. Biochem. Soc. Trans. 33, 331-334.
Qian, F., Frankfater, A., Steiner, D. F., Bajkowski, A. S. and Chan, S. J. 1991. Characterization of multiple cathepsin B mRNAs in murine B16a melanoma. Anticancer Res. 11, 1445-1451.
Qin, Y., Cao, X., Guo, J., Zhang, Y., Pan, L., Zhang, H., Li, H., Tang, C., Du, J. and Shi, G. P. 2012. Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Cardiovasc. Res. 96, 401-410.
Rofstad, E. K., Mathiesen, B., Kindem, K. and Galappathi, K. 2006. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res. 66, 6699-6707.
Ruan, H., Hao, S., Young, P. and Zhang, H. 2015. Targeting cathepsin B for cancer therapies. Horiz. Cancer Res. 56, 23-40.
Ruan, J., Zheng, H., Rong, X., Rong, X., Zhang, J., Fang, W., Zhao, P. and Luo, R. 2016. Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients. Mol. Cancer 15, 17.
Ruckrich, T., Brandenburg, J., Cansier, A., Muller, M., Stevanovic, S., Schilling, K., Wiederanders, B., Beck, A., Melms, A., Reich, M., Driessen, C. and Kalbacher, H. 2006. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. Biol. Chem. 387, 1503-1511.
Ruffell, B., Affara, N. I., Cottone, L., Junankar, S., Johansson, M., DeNardo, D. G., Korets, L., Reinheckel, T., Sloane, B. F., Bogyo, M. and Coussens, L. M. 2013. Cathepsin C is a tissue-specific regulator of squamous carcinogenesis. Genes Dev. 27, 2086-2098.
Santamaria, I., Velasco, G., Cazorla, M., Fueyo, A., Campo, E. and Lopez-Otin, C. 1998. Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res. 58, 1624-1630.
Saraste, A. and Pulkki, K. 2000. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc. Res. 45, 528-537.
Satelur, K. P. and Kumar, G. S. 2017. Immunohistochemical expression of cathepsin D in primary and recurrent squamous cell carcinoma. J. Contemp. Dent. Pract. 18, 795-801.
Schweiger, A., Christensen, I. J., Nielsen, H. J., Sorensen, S., Brunner, N. and Kos, J. 2004. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int. J. Biol. Markers 19, 289-294.
Seo, B. R., Min, K. J., Woo, S. M., Choe, M., Choi, K. S., Lee, Y. K., Yoon, G. and Kwon, T. K. 2017. Inhibition of cathepsin S induces mitochondrial ROS that sensitizes TRAIL-mediated apoptosis through p53-mediated downregulation of Bcl-2 and c-FLIP. Antioxid. Redox Signal. 27, 215-233.
Seo, S. U., Woo, S. M., Min, K. J. and Kwon, T. K. 2018. Z-FL-COCHO, a cathepsin S inhibitor, enhances oxaliplatin- induced apoptosis through upregulation of Bim expression. Biochem. Biophys. Res. Commun. 498, 849-854.
Shi, G. P., Sukhova, G. K., Kuzuya, M., Ye, Q., Du, J., Zhang, Y., Pan, J. H., Lu, M. L., Cheng, X. W., Iguchi, A., Perrey, S., Lee, A. M., Chapman, H. A. and Libby, P. 2003. Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. 92, 493-500.
Singh, N., Das, P., Gupta, S., Sachdev, V., Srivasatava, S., Datta Gupta, S., Pandey, R. M., Sahni, P., Chauhan, S. S. and Saraya, A. 2014. Plasma cathepsin L: a prognostic marker for pancreatic cancer. World J. Gastroenterol. 20, 17532-17540.
Sivaparvathi, M., Sawaya, R., Chintala, S. K., Go, Y., Gokaslan, Z. L. and Rao, J. S. 1996. Expression of cathepsin D during the progression of human gliomas. Neurosci. Lett. 208, 171-174.
Small, D. M., Burden, R. E., Jaworski, J., Hegarty, S. M., Spence, S., Burrows, J. F., McFarlane, C., Kissenpfennig, A., McCarthy, H. O., Johnston, J. A., Walker, B. and Scott, C. J. 2013. Cathepsin S from both tumor and tumor-associated cells promote cancer growth and neovascularization. Int. J. Cancer 133, 2102-2112.
Sukhova, G. K., Shi, G. P., Simon, D. I., Chapman, H. A. and Libby, P. 1998. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 102, 576-583.
Sukhova, G. K., Zhang, Y., Pan, J. H., Wada, Y., Yamamoto, T., Naito, M., Kodama, T., Tsimikas, S., Witztum, J. L., Lu, M. L., Sakara, Y., Chin, M. T., Libby, P. and Shi, G. P. 2003. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor- deficient mice. J. Clin. Invest. 111, 897-906.
Tsai, J. Y., Lee, M. J., Chang, M. D., Wang, H. C., Lin, C. C. and Huang, H. 2014. Effects of novel human cathepsin S inhibitors on cell migration in human cancer cells. J. Enzyme Inhib. Med. Chem. 29, 538-546.
Tsushima, H., Ueki, A., Matsuoka, Y., Mihara, H. and Hopsu- Havu, V. K. 1991. Characterization of a cathepsin-H-like enzyme from a human melanoma cell line. Int. J. Cancer 48, 726-732.
Turk, B. 2006. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 5, 785-799.
Turk, B., Bieth, J. G., Bjork, I., Dolenc, I., Turk, D., Cimerman, N., Kos, J., Colic, A., Stoka, V. and Turk, V. 1995. Regulation of the activity of lysosomal cysteine proteinases by pHinduced inactivation and/or endogenous protein inhibitors, cystatins. Biol. Chem. Hoppe Seyler 376, 225-230.
Turk, V., Kos, J. and Turk, B. 2004. Cysteine cathepsins (proteases)--on the main stage of cancer? Cancer Cell 5, 409-410.
Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B. and Turk, D. 2012. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 1824, 68-88.
Uchiyama, Y. 2001. Autophagic cell death and its execution by lysosomal cathepsins. Arch. Histol. Cytol. 64, 233-246.
Vasiljeva, O., Reinheckel, T., Peters, C., Turk, D., Turk, V. and Turk, B. 2007. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13, 387-403.
Vazquez-Ortiz, G., Pina-Sanchez, P., Vazquez, K., Duenas, A., Taja, L., Mendoza, P., Garcia, J. A. and Salcedo, M. 2005. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 5, 68.
Verbovsek, U., Motaln, H., Rotter, A., Atai, N. A., Gruden, K., Van Noorden, C. J. and Lah, T. T. 2014. Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma. PLoS One 9, e111819.
Villadangos, J. A., Bryant, R. A., Deussing, J., Driessen, C., Lennon-Dumenil, A. M., Riese, R. J., Roth, W., Saftig, P., Shi, G. P., Chapman, H. A., Peters, C. and Ploegh, H. L. 1999. Proteases involved in MHC class II antigen presentation. Immunol. Rev. 172, 109-120.
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., 2nd, Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., Bigner, D. D., Friedman, A. H. and Friedman, H. S. 2007. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 13, 1253-1259.
Waghray, A., Keppler, D., Sloane, B. F., Schuger, L. and Chen, Y. Q. 2002. Analysis of a truncated form of cathepsin H in human prostate tumor cells. J. Biol. Chem. 277, 11533-11538.
Wang, Z. and Zhao, X. 1998. [Expression and prognostic relation of cathepsin D in non-small cell lung cancer tissues and lymph nodes]. Zhonghua Jie He He Hu Xi Za Zhi 21, 164-166.
Ward, C., Kuehn, D., Burden, R. E., Gormley, J. A., Jaquin, T. J., Gazdoiu, M., Small, D., Bicknell, R., Johnston, J. A., Scott, C. J. and Olwill, S. A. 2010. Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. PLoS One 5, pii: e12543.
Xu, J., Li, D., Ke, Z., Liu, R., Maubach, G. and Zhuo, L. 2009. Cathepsin S is aberrantly overexpressed in human hepatocellular carcinoma. Mol. Med. Rep. 2, 713-718.
Yang, M., Liu, J., Shao, J., Qin, Y., Ji, Q., Zhang, X. and Du, J. 2014. Cathepsin S-mediated autophagic flux in tumor-associated macrophages accelerate tumor development by promoting M2 polarization. Mol. Cancer 13, 43.
Yang, Y., Lim, S. K., Choong, L. Y., Lee, H., Chen, Y., Chong, P. K., Ashktorab, H., Wang, T. T., Salto-Tellez, M., Yeoh, K. G. and Lim, Y. P. 2010. Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J. Proteome Res. 9, 4767-4778.
Zhang, L., Wang, H., Xu, J., Zhu, J. and Ding, K. 2014. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol. Lett. 228, 248-259.
Zhao, Y. and Adjei, A. A. 2015. Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor. Oncologist 20, 660-673.
Zhu, D. M. and Uckun, F. M. 2000. Cathepsin inhibition induces apoptotic death in human leukemia and lymphoma cells. Leuk. Lymphoma 39, 343-354.
Zhu, D. M. and Uckun, F. M. 2000. Z-Phe-Gly-NHO-Bz, an inhibitor of cysteine cathepsins, induces apoptosis in human cancer cells. Clin. Cancer Res. 6, 2064-2069.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.